CCM
TSHA icon

Coldstream Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Coldstream Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-207
Closed -$288 – 3196
2025
Q1 		$288 Buy
+207
New +$346 ﹤0.01% 3451

Other funds holding TSHA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Coldstream Capital Management's TSHA Position: Q2 2025 in Review

Coldstream Capital Management sold out of Taysha Gene Therapies (TSHA) in Q2 2025, closing a stake of 207 shares — an estimated $288 sold.

Coldstream Capital Management first reported a position in TSHA in Q1 2025 and held it in 1 quarter. The position peaked at $288 in Q1 2025. 150 funds tracked by Wall St. Rank hold TSHA as of Q2 2025.

  • Coldstream Capital Management reported no remaining Taysha Gene Therapies position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 207 Taysha Gene Therapies shares in Q2 2025, an estimated $288.
  • Coldstream Capital Management first reported a position in Taysha Gene Therapies in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Taysha Gene Therapies position peaked at $288 in Q1 2025.
  • 150 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.